dialysis

News

Unicycive hits another hurdle with hyperphosphataemia drug

Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in dialysis patients have been knocked back again.

Patients

Hands holding graphic representation of a kidney on a blue background

The forgotten few: Why the kidney transplant system is faili...

While innovation has reshaped therapeutic areas like oncology, transplant medicine has, by comparison, stood still.

News

dialysis machine at patient hospital bedside

Baxter slims down again, selling kidney division to Carlyle

Baxter International has agreed to sell its kidney treatment division to private equity firm Carlyle Group in a $3.8 billion cash deal, continuing its efforts to streamline its operations a

Patients

Spotlight on kidney disease: Driving change for patients

Katherine Forbes, director of innovation and enterprise at Kidney Research UK, discusses the unique, evolving role of medical research charities in facilitating collaborative partnerships a

News

Study warns of chronic kidney disease timebomb

Up to one in six people in eight industrialised nations could be suffering from chronic kidney disease (CKD) by 2032, with dire consequences for “patients, [the] planet, a

News

Akebia joins GSK in US market for oral CKD anaemia drugs

The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS

Unicycive hits another hurdle with hyperphosphataemia drug

The forgotten few: Why the kidney transplant system is faili...

Baxter slims down again, selling kidney division to Carlyle

Spotlight on kidney disease: Driving change for patients

Study warns of chronic kidney disease timebomb

Akebia joins GSK in US market for oral CKD anaemia drugs

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

dialysis

Editor's Picks